Jamison Private Wealth Management Inc. Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Jamison Private Wealth Management Inc. lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 0.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 27,193 shares of the company’s stock after buying an additional 172 shares during the quarter. Jamison Private Wealth Management Inc.’s holdings in AstraZeneca were worth $2,119,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Cox Capital Mgt LLC purchased a new stake in AstraZeneca during the 1st quarter valued at $2,683,000. TD Asset Management Inc increased its holdings in AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after buying an additional 121,876 shares in the last quarter. Northcape Wealth Management LLC purchased a new position in AstraZeneca in the 2nd quarter worth about $269,000. Wealthcare Advisory Partners LLC lifted its stake in AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock valued at $416,000 after acquiring an additional 543 shares during the period. Finally, Cetera Advisors LLC boosted its holdings in shares of AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after acquiring an additional 54,488 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the subject of several research reports. TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Barclays raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $77.85 on Wednesday. The business has a 50-day simple moving average of $81.31 and a two-hundred day simple moving average of $78.04. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a market cap of $241.38 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 1.44 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.08 EPS. On average, analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Cuts Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a $0.49 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s payout ratio is presently 47.34%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.